恒瑞医药：HRS-6257片获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-6257 tablets, aimed at treating acute and chronic pain, with no similar drugs approved in the domestic market [1] Company Summary - Heng Rui Medicine's subsidiary, Shanghai Heng Rui Medicine Co., Ltd., has been granted a Clinical Trial Approval Notice for HRS-6257 tablets [1] - The total research and development investment for the HRS-6257 project has reached approximately 15.58 million yuan [1] Industry Summary - Currently, there are no approved drugs targeting the same mechanism as HRS-6257 in the domestic market [1]